Company Profile
Wockhardt is a pharmaceutical and biotech company, globally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products.
It also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia.
Its portfolio also includes FOVISCU, an antibiotic for gram-negative infections, MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens, and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy.
Additionally, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products. Its portfolio also includes Biovac-B, a recombinant hepatitis-B vaccine, Wepox, a recombinant human erythropoietin, Wosulin, a recombinant human insulin, and Glaritus, a recombinant insulin glargine Delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Founded in 1967, Wockhardt is headquartered in Mumbai, India.